(19)
(11) EP 4 253 446 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
05.03.2025 Bulletin 2025/10

(45) Mention of the grant of the patent:
29.01.2025 Bulletin 2025/05

(21) Application number: 21897913.6

(22) Date of filing: 22.11.2021
(51) International Patent Classification (IPC): 
C08G 65/334(2006.01)
C09D 171/02(2006.01)
C12N 5/0775(2010.01)
C08F 293/00(2006.01)
C12M 3/00(2006.01)
C08B 37/16(2006.01)
(52) Cooperative Patent Classification (CPC):
C09D 171/02; C08G 65/334; C08B 37/0015; C08L 5/16; C09D 105/16; C08G 65/3346; C08G 65/3318; C12N 5/0653; C12N 2533/30; C12N 2506/1346; C08F 2438/03; C08F 293/005; C08G 83/007
(86) International application number:
PCT/JP2021/042821
(87) International publication number:
WO 2022/113940 (02.06.2022 Gazette 2022/22)

(54)

POLYROTAXANE HAVING AMINO GROUP

POLYROTAXAN MIT AMINOGRUPPE

POLYROTAXANE POSSÉDANT UN GROUPE AMINO


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 26.11.2020 JP 2020196319

(43) Date of publication of application:
04.10.2023 Bulletin 2023/40

(73) Proprietors:
  • Denka Company Limited
    Tokyo 103-8338 (JP)
  • Institute of Science Tokyo
    Tokyo 152-8550 (JP)

(72) Inventors:
  • AOYAMA SEKIYA, Ruriko
    Tokyo 103-8338 (JP)
  • ARISAKA, Yoshinori
    Tokyo 113-8510 (JP)
  • YUI, Nobuhiko
    Tokyo 113-8510 (JP)
  • IWATA, Takanori
    Tokyo 113-8510 (JP)
  • YODA, Tetsuya
    Tokyo 113-8510 (JP)
  • HAKARIYA, Masahiro
    Tokyo 113-8510 (JP)
  • MASUDA, Hiroki
    Tokyo 113-8510 (JP)

(74) Representative: Gulde & Partner 
Patent- und Rechtsanwaltskanzlei mbB Berliner Freiheit 2
10785 Berlin
10785 Berlin (DE)


(56) References cited: : 
EP-A1- 1 419 791
WO-A1-2017/039294
JP-A- 2006 094 799
WO-A1-03/074099
WO-A1-2017/191827
   
  • ATSUSHI TAMURA ET AL: "Supramolecular flower micelle formation of polyrotaxane-containing triblock copolymers prepared from macro-chain transfer agents bearing molecular hooks", POLYMER CHEMISTRY, vol. 5, no. 15, 1 January 2014 (2014-01-01), Cambridge, pages 4511, XP055363882, ISSN: 1759-9954, DOI: 10.1039/c4py00379a
  • ARISAKA YOSHINORI ET AL: "Tethered bone morphogenetic protein-2 onto sulfonated-polyrotaxane based surfaces promotes osteogenic differentiation of MC3T3-E1 cells", JOURNAL OF BIOMATERIALS SCIENCE. POLYMER EDITION, VSP, UTRECHT, NL, vol. 28, no. 10-12, 13 August 2017 (2017-08-13), pages 974 - 985, XP009536866, ISSN: 0920-5063, DOI: 10.1080/09205063.2017.1319095
  • RAJENDRAN ARUN KUMAR ET AL: "Sulfonated Polyrotaxane Surfaces with Basic Fibroblast Growth Factor Alter the Osteogenic Potential of Human Mesenchymal Stem Cells in Short-Term Culture", HHS AUTHOR MANUSCRIPTS, vol. 5, no. 11, 11 November 2019 (2019-11-11), US, pages 5652 - 5659, XP055869712, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acsbiomaterials.8b01343> DOI: 10.1021/acsbiomaterials.8b01343
  • MASUDA HIROKI ET AL: "Biological Effects of Polyrotaxane Surfaces on Cellular Responses of Fibroblast, Preosteoblast and Preadipocyte Cell Lines", POLYMERS, vol. 12, no. 4, 16 April 2020 (2020-04-16), pages 924, XP055929406, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240480/pdf/polymers-12-00924.pdf> DOI: 10.3390/polym12040924
  • RAJENDRAN ARUN KUMAR, ARISAKA YOSHINORI, ISEKI SACHIKO, YUI NOBUHIKO: "Sulfonated Polyrotaxane Surfaces with Basic Fibroblast Growth Factor Alter the Osteogenic Potential of Human Mesenchymal Stem Cells in Short-Term Culture", HHS AUTHOR MANUSCRIPTS, NIH- NATIONAL LIBRARY OF MEDICINE, US, vol. 5, no. 11, 11 November 2019 (2019-11-11), US , pages 5652 - 5659, XP055869712, DOI: 10.1021/acsbiomaterials.8b01343
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).